enGene Therapeutics
ENGN
61 hedge funds and large institutions have $382M invested in enGene Therapeutics in 2026 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 8 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
7% more funds holding
Funds holding: 57 → 61 (+4)
3.82% less ownership
Funds ownership: 87.63% → 83.81% (-3.8%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
28% less capital invested
Capital invested by funds: $530M → $382M (-$148M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$17.1M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.2M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$9.88M |
| 4 |
BOCH
Blue Owl Capital Holdings
New York
|
+$9.4M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$3.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$36.1M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$17.1M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$8.58M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$6M |
| 5 |
Morgan Stanley
New York
|
-$5.63M |
ENGN Hedge Fund Activity: Q1 2026 in Review
61 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q1 2026, worth a combined $382M — down 28% from $530M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ENGN positions and 8 closed out — a net gain of 4 holders — while 22 added to existing stakes and 14 trimmed.
The largest buyer was Siren LLC, adding an estimated $17.1M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $36.1M sold.
- 61 institutional investors held enGene Therapeutics (ENGN) as of Q1 2026, up from 57 in Q4 2025.
- Funds reported $382M of enGene Therapeutics stock for Q1 2026, down 28% quarter-over-quarter.
- 12 funds opened new enGene Therapeutics positions in Q1 2026 and 8 closed out, a net change of +4 holders.
- The largest enGene Therapeutics buyer in Q1 2026 was Siren LLC, an estimated $17.1M added.
- The largest enGene Therapeutics seller in Q1 2026 was Cormorant Asset Management, an estimated $36.1M sold.
Based on aggregated 13F filings for Q1 2026.